Navigation Links
Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
Date:7/21/2011

ng DGT Holdings, Derycz Scientific, Miller Energy Resources, Sensis Corporation and Coast Plating. He is also a member of the Advisory Board of the L.A. Film School.  

In 2008, General McPeak was a national co-chairman of Obama for President, and in 2010 the President appointed him to the American Battle Monuments Commission, responsible for supervising the 24 cemeteries and 25 memorials in 15 countries overseas that commemorate the achievements and sacrifices of the men and women of our Armed Forces. In 2011, the Commission elected him its chairman.

General McPeak was a distinguished graduate of the San Diego State College ROTC program in 1957, and received the university's first ever Lifetime Achievement Award in 1992. He also holds a Master's in International Relations from George Washington University.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genesis Biopharma Names David Voyticky to Board of Directors
2. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
3. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
4. Genesis Biopharma Conference Call and Webcast Reminder
5. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
6. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
7. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
8. ThermoGenesis Announces China Customer Implements Cord Blood Products
9. Tissue Genesis Begins FDA-Approved Clinical Trial
10. CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
11. Organogenesis, Life Sciences Center Break Ground on Worlds Largest Automated Living Cell Manufacturing Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous ... quarter ended June 30, 2015, corporate highlights, and ... report are available at www.sedar.com ,  ... "RepliCel expects to launch its RCS-01 ...
(Date:8/27/2015)... ... 27, 2015 , ... The Kansas City Animal Health Investment ... health companies to hear from animal health companies with the newest technology. Companies ... agreements or distribution contracts. This meeting is one of the only investment ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
(Date:8/27/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2015. Biorem,s complete second quarter financial statements and MD&A have been ... except earnings per shareThree-months ended , Six -months endedJune 30 , ... , 2014 Revenue , 4,709 , ... , 1,656 , 56 , 3,188 ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... on its flagship,suite of medication and infusion management ... and an industry-first Performance,Analytics Service that provides hospitals ... , The ... features that can help hospitals increase the security ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... in a panel,discussion at the 2008 RBC Capital Marketing Healthcare ... Rheumatology", will take,place on Wednesday, December 10, 2008 at 10:00 ... City. , To access ...
... - Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority ... patients with genotypes 2 and 3 chronic hepatitis C - ... receiving 900-mcg Albuferon had comparable rates of serious adverse events, ... peginterferon alfa-2a - , , ...
Cached Biology Technology:Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... of 45 genes coding for antibacterial drug resistance ... of hospital-acquired infections worldwide. The study was ... "We expected to find resistance genes," said lead ... Genomic Information Laboratory at France's National Center for ...
... The octopus arm is extremely flexible. Thanks to ... virtually infinite number of "degrees of freedom"--the octopus ... movements that is unmatched by the human arm. ... differences between the octopus and vertebrates, the octopus ...
... in 1 in every 1,000 births and cause 1 in 20 ... failure of cells within the neural tube to migrate to the ... study in this week's issue of Nature is the first to ... the correct local within the developing neural tube of vertebrates. ...
Cached Biology News:Supersized 'island' of resistance genes discovered in an infectious bacterium 2How the octopus forms an elbow 2
... an automated, confocal, real-time, single cell kinetic ... integrated into a single, compact unit. ... high-resolution, automated confocal imaging with sophisticated imaging ... assays. The system allows the user to ...
... E-PAGE Gels easier and more efficient by ... several types of pre-cut pre-assembled membrane/filter paper ... 13.5 cm E-PAGE Gels*. The available nitrocellulose ... western transfer of proteins (Figure 1 Table ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... CAST Equine EIA Principle: ... LTC4, LTD4 and LTE4 are ... by 5-lipoxygenase and glutathione-S-transferase. In ... termed "Slow Reacting Substances of ...
Biology Products: